Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 18
526
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Melognine, a novel monoterpenoid indole alkaloid from Melodinus fusiformis that induce apoptosis in BT549 cells

ORCID Icon, , &
Pages 3004-3010 | Received 17 Jul 2019, Accepted 08 Oct 2019, Published online: 01 Nov 2019
 

Abstract

A novel monoterpenoid indole alkaloid, melognine (1) possessing an unprecedented skeleton with a 6/6/5/5/6/6 hexatomic rearranged ring system was isolated from the stems of Melodinus fusiformis. The structure with absolute configuration of 1 was established by extensive spectroscopic analyses and quantum ECD calculations. Melognine showed significant cytotoxicity on human breast cancer BT549 cells with an IC50 value of 1.49 μM by MTT assay. Further mechanism of action study indicated that melognine demonstrated the ability to induce apoptosis by activation of caspase-3 and p53, and downregulation of Bcl-2 in BT549 cells.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This research was funded by Natural Science Foundation of China (21772065), Shandong Provincial Natural Science Foundation (ZR2017MH019), and Shandong Provincial Key Research Project (2018GSF118158, 2017GSF19111).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.